Media stories about Compugen (NASDAQ:CGEN) have been trending somewhat negative this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Compugen earned a daily sentiment score of -0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6005185915843 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Compugen (NASDAQ:CGEN) opened at $2.50 on Friday. Compugen has a 1-year low of $2.25 and a 1-year high of $6.05.
Separately, Zacks Investment Research cut shares of Compugen from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.